Selpercatinib and pralsetinib are preferred first-line therapy options for patients with RET fusion-positive metastatic NSCLC and are recommended as subsequent therapies if RET inhibitors have not been used in the first-line setting (29). Here, RET is linked to non-small cell lung carcinoma.